



上海源叶生物科技有限公司
Shanghai yuanye Bio-Technology Co., Ltd
电话: 021-61312973 传真: 021-55068248
网址: www.shyuanye.com
邮箱: shyysw@sina.com

产品名称: **Topiroxostat**
产品别名: 托匹司他; **FYX-051**

生物活性:					
Description	Topiroxostat (FYX-051) is a potent and orally active xanthine oxidoreductase (XOR) inhibitor with an IC50 value of 5.3 nM and a Ki value of 5.7 nM. Topiroxostat exhibits weak CYP3A4-inhibitory activity (18.6%). Topiroxostat has the potential for hyperuricemia treatment[1][2].				
IC50 & Target	IC50: 5.3 nM (XOR)[1] Ki: 5.7 nM (XOR)[2]				
In Vitro	These potent and more sustained effects of Topiroxostat (FYX-051, compound 39) have been confirmed by a crystallographic analysis of XOR-Topiroxostat complex. The cyano group of Topiroxostat has been reported to play an important role in the binding activity between Topiroxostat and XOR. This is attributable to the formation of a hydrogen bond between Asn 768 of XOR and the cyano group of Topiroxostat[1].				
In Vivo	Topiroxostat (FYX-051; 0.03-10 mg/kg; oral administration; for 1 hour; male Wistar/ST strain rats) treatment shows a potent and long-lasting hypouricemic effect in a rat model of potassium oxonate-induced hyperuricemia[2] . The C _{max} and bioavailability of Topiroxostat (FYX-051, compound 39) are as high as 4.62 µg/mL (3 mg/kg) and 69.6%, respectively. Moreover, the t _{1/2} value of Topiroxostat is 19.7 hours[1].				
	Animal Model:	Male Wistar/ST strain rats (7 weeks old) injected with potassium oxonate[2]			
	Dosage:	0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg			
	Administration:	Oral administration; for 1 hour			
	Result:	Caused a dose-dependent decrease in serum urate levels with an extremely low ED ₅₀ of 0.15 mg/kg, evaluated at 1 h after oral administration.			
Solvent&Solubility	In Vitro: DMSO : 23.5 mg/mL (94.67 mM; Need ultrasonic and warming)				
	Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
		1 mM	4.0284 mL	20.1418 mL	40.2836 mL
		5 mM	0.8057 mL	4.0284 mL	8.0567 mL
		10 mM	0.4028 mL	2.0142 mL	4.0284 mL
	*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液; 一旦配成溶液, 请分装保存, 避免反复冻融造成的产品失效。 储备液的保存方式和期限 -80℃, 6 months; -20℃, 1 month。 -80℃ 储存时, 请在 6 个月内使用, -20℃ 储存时, 请在 1 个月内使用。				
References	[1]. Sato T, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected]. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9. [2]. Matsumoto K, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011 Jan;336(1):95-103.				